151 related articles for article (PubMed ID: 35267415)
21. Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity.
Cao X; Liu P; Gao XS; Shang S; Liu J; Wang Z; Su M; Ding X
Front Oncol; 2022; 12():812031. PubMed ID: 35847952
[TBL] [Abstract][Full Text] [Related]
22. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
23. Significant Reduction in Vertebral Artery Dose by Intensity Modulated Proton Therapy: A Pilot Study for Nasopharyngeal Carcinoma.
Lin YH; Cheng JY; Huang BS; Luo SD; Lin WC; Chou SY; Juang PJ; Li SH; Huang EY; Wang YM
J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442466
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal Assessment of Quality of Life in Nasopharyngeal Cancer Patients Treated with Intensity-Modulated Proton Therapy and Volumetric Modulated Arc Therapy at Different Time Points.
Liao KC; Huang YJ; Tsai WL; Lee CH; Fang FM
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539552
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
26. Sparing Cardiac Substructures With Optimized Volumetric Modulated Arc Therapy and Intensity Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-small Cell Lung Cancer.
Ferris MJ; Martin KS; Switchenko JM; Kayode OA; Wolf J; Dang Q; Press RH; Curran WJ; Higgins KA
Pract Radiat Oncol; 2019; 9(5):e473-e481. PubMed ID: 31077884
[TBL] [Abstract][Full Text] [Related]
27. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
[TBL] [Abstract][Full Text] [Related]
28. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation.
Widesott L; Pierelli A; Fiorino C; Dell'oca I; Broggi S; Cattaneo GM; Di Muzio N; Fazio F; Calandrino R; Schwarz M
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):589-96. PubMed ID: 18793962
[TBL] [Abstract][Full Text] [Related]
29. Towards the clinical implementation of intensity-modulated proton therapy for thoracic indications with moderate motion: Robust optimised plan evaluation by means of patient and machine specific information.
Ribeiro CO; Visser S; Korevaar EW; Sijtsema NM; Anakotta RM; Dieters M; Both S; Langendijk JA; Wijsman R; Muijs CT; Meijers A; Knopf A
Radiother Oncol; 2021 Apr; 157():210-218. PubMed ID: 33545257
[TBL] [Abstract][Full Text] [Related]
30. ART for head and neck patients: On the difference between VMAT and IMPT.
Góra J; Kuess P; Stock M; Andrzejewski P; Knäusl B; Paskeviciute B; Altorjai G; Georg D
Acta Oncol; 2015; 54(8):1166-74. PubMed ID: 25850583
[TBL] [Abstract][Full Text] [Related]
31. Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses.
Dutz A; Lühr A; Troost EGC; Agolli L; Bütof R; Valentini C; Baumann M; Vermeren X; Geismar D; Timmermann B; Krause M; Löck S
Radiother Oncol; 2021 Jul; 160():69-77. PubMed ID: 33872640
[TBL] [Abstract][Full Text] [Related]
32. Potential benefits of adaptive intensity-modulated proton therapy in nasopharyngeal carcinomas.
Minatogawa H; Yasuda K; Dekura Y; Takao S; Matsuura T; Yoshimura T; Suzuki R; Yokota I; Fujima N; Onimaru R; Shimizu S; Aoyama H; Shirato H
J Appl Clin Med Phys; 2021 Jan; 22(1):174-183. PubMed ID: 33338323
[TBL] [Abstract][Full Text] [Related]
33. The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study.
De Rose F; Cozzi L; Meattini I; Fogliata A; Franceschini D; Franzese C; Tomatis S; Becherini C; Livi L; Scorsetti M
Clin Oncol (R Coll Radiol); 2020 Jan; 32(1):26-34. PubMed ID: 31377082
[TBL] [Abstract][Full Text] [Related]
34. Post-Irradiation Sinus Mucosa Disease in Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Proton Therapy.
Wu PW; Huang CC; Lee YS; Chou YC; Fan KH; Lin CY; Huang BS; Yang SW; Huang CC; Chang PH; Lee TJ; Chang JT
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008389
[TBL] [Abstract][Full Text] [Related]
35. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
Seco J; Gu G; Marcelos T; Kooy H; Willers H
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
[TBL] [Abstract][Full Text] [Related]
36. First experience with model-based selection of head and neck cancer patients for proton therapy.
Tambas M; Steenbakkers RJHM; van der Laan HP; Wolters AM; Kierkels RGJ; Scandurra D; Korevaar EW; Oldehinkel E; van Zon-Meijer TWH; Both S; van den Hoek JGM; Langendijk JA
Radiother Oncol; 2020 Oct; 151():206-213. PubMed ID: 32768508
[TBL] [Abstract][Full Text] [Related]
37. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
[TBL] [Abstract][Full Text] [Related]
38. Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer.
Celik E; Baus W; Baues C; Schröder W; Clivio A; Fogliata A; Scorsetti M; Marnitz S; Cozzi L
Radiat Oncol; 2020 May; 15(1):120. PubMed ID: 32448296
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
Manzar GS; Lester SC; Routman DM; Harmsen WS; Petersen MM; Sloan JA; Mundy DW; Hunzeker AE; Amundson AC; Anderson JL; Patel SH; Garces YI; Halyard MY; McGee LA; Neben-Wittich MA; Ma DJ; Frank SJ; Whitaker TJ; Foote RL
Radiother Oncol; 2020 Jun; 147():64-74. PubMed ID: 32234612
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
